Accessibility Tools
 Inflammasome Therapeutics - Jayakrishna Ambati, M.D.

Jayakrishna Ambati, M.D.

Co-Founder and Board Member

After graduating from Johns Hopkins University at 17 years of age, Jayakrishna Ambati has gone on to become one of the world's leading authorities on degenerative diseases. His laboratory first reported the link between Alu-RNA, inflammasome activation, and geographic atrophy in the journal Science in 2014, establishing the scientific foundation on which the Kamuvudine platform is built.